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Key pointsThis systematic review presents an overview of the value of all published biological tumor markers to predict local control in laryngeal cancer patients treated with definitive radiotherapy.The data show that cell proliferation could be of potential interest for predicting local control in laryngeal cancer patients treated with primary radiotherapy.EGFR and p53 are not predictive of local control after primary radiotherapy in laryngeal cancer patients.

1. INTRODUCTION {#coa13540-sec-0009}
===============

Worldwide, laryngeal cancer is diagnosed in 157 000 patients and is responsible for 83 000 deaths each year.[^1^](#coa13540-bib-0001){ref-type="ref"} Treatment of laryngeal cancer is nowadays highly focused on laryngeal preservation, retaining the main functions of the of the larynx, speech, breathing and swallowing, with primary radiotherapy as one of the most important treatment modalities. Despite relatively early diagnosis and efforts to improve treatments, overall survival rates have not significantly improved over the last 30 years.[^2^](#coa13540-bib-0002){ref-type="ref"} Currently, the choice of treatment in laryngeal cancer is mainly based on tumor stage, post‐treatment morbidity and quality of life.[^3^](#coa13540-bib-0003){ref-type="ref"} Besides these clinicopathological and patient factors, biological tumor markers might be of potential clinical relevance. The aim of this systematic review was to identify predictive biological tumor markers that are relevant for the outcome of primary radiotherapy in laryngeal cancer. The main endpoint for outcome after primary radiotherapy was local control. Most common definitions for local control were as follows: time to local disease‐free survival and presence of local recurrence within two years.

2. METHODS {#coa13540-sec-0010}
==========

2.1. Search strategy {#coa13540-sec-0011}
--------------------

A literature search was performed in PubMed, Embase, and in the Cochrane Library on 19 July 2018, to identify studies on predictive biological tumor markers in laryngeal cancer patients primarily treated by radiotherapy. The search was updated on 23 May 2019. An extensive search was performed using keywords as well as free search terms on the following items: a) laryngeal cancer; b) radiotherapy or chemoradiation; c) biological tumor markers or common detection methods used in prognostic marker studies; and d) prognosis or response. The final search strategy used is shown in Table [S1](#coa13540-sup-0001){ref-type="supplementary-material"}.

2.2. Selection criteria {#coa13540-sec-0012}
-----------------------

A title, abstract and finally manuscript selection was performed, using the following exclusion criteria: a) non‐English articles; b) tumor site other than larynx; c) treatment modalities other than primary radiotherapy; d) markers not studied in primary tumor tissue, for example serum tumor markers; e) no biological tumor marker studied; f) outcome other than radiotherapy response or locoregional recurrence reported; g) cell lines or xenograft models; and h) non‐original research articles, for example reviews, case reports. Title, abstract and manuscript selection, as well as data extraction and quality assessment, was performed by two independent researchers (MGN and EAK).

2.3. Data extraction {#coa13540-sec-0013}
--------------------

From the papers included in this systematic review, the following data were extracted and recorded in a predefined database: a) year of publication; b) number of patients; c) retrospective or prospective patient selection; d) patient\'s characteristics: age, gender, stage and location; e) details on radiotherapy; f) details on the assay used: assay method, cut‐offs, number of positive and negative tumors; and g) results of the analysis to evaluate the relation between the marker and outcome of radiotherapy. This could be either results of survival analysis for local disease‐free survival (log‐rank analysis and Cox regression) or, in case of matched‐control study results of the chi‐square test, logistic regression analysis, *t*‐test or Mann‐Whitney U test. Biological tumor markers were clustered on biological function.

2.4. Study quality {#coa13540-sec-0014}
------------------

Study quality assessment was based on the REMARK (REporting recommendations for tumor MARKer prognostic studies) criteria from McShane et al[^4^](#coa13540-bib-0004){ref-type="ref"} A comparable quality measurement form was used previously in a systematic review.[^5^](#coa13540-bib-0005){ref-type="ref"} In short, the following items were explored: 1) four out of six of the following patient and tumor characteristics were described: age, gender, tumor location, T‐stage, N‐stage and differentiation grade; 2) the study reported inclusion and exclusion criteria; 3) the radiotherapy treatment schedule was well described; 4) definition of the study endpoint was given; 5) the relation between marker and outcome was sufficiently described; 6) a rational for number of patient tested was given; 7.1) the assay used to measure biomarker expression was sufficiently described, 7.2) as well as interpretation of the assay; 8) the follow‐up time of patients in the study was described; 9) the study reported how many patients were available for statistical analysis; and 10) limitations of the study were described. A maximum of 11 points could be allocated to an article. To compare quality scores, the Mann‐Whitney U test was used.

2.5. Data analysis {#coa13540-sec-0015}
------------------

Results of the analysis describing the relation between a marker and local control after radiotherapy were compared. *P*‐values of \<.05 were considered statistically significant. *P*‐values of \<.10 were considered as a trend (explicitly stated).

A biological tumor marker was considered as a potential marker for local control if \>50% of the studies investigating the marker described a relation with either poor or good local control after radiotherapy. In case the study results were sufficiently described in the manuscript, but only a *P*‐value was presented, the Odds ratio (OR) and 95% confidence interval (CI) were calculated (explicitly stated).[^6^](#coa13540-bib-0006){ref-type="ref"} This enabled us to compare results of various studies reporting on the same biological tumor marker better. Also, to uniformly present the data, "positive" expression is used as indicator; in case a manuscript presented the results with "negative" expression as indicator, we inverted the OR or Hazard Ratio (HR) and 95%CI.

2.6. Data availability statement {#coa13540-sec-0016}
--------------------------------

The data that support the findings of this study are available from the corresponding author upon request.

3. RESULTS {#coa13540-sec-0017}
==========

In total, 400 (English n = 359) manuscripts were identified in PubMed and 435 (English n = 427) in Embase. No Cochrane review was available. After removal of duplicate publications, 651 were further analysed. Figure [1](#coa13540-fig-0001){ref-type="fig"} shows a flow chart of selection process. Finally, 52 studies describing 118 markers could be included. Remarkably, all of the included studies were identified in PubMed, and no additional were found in Embase.

![Flow chart of selection process](COA-45-486-g001){#coa13540-fig-0001}

3.1. Study characteristics and study quality {#coa13540-sec-0018}
--------------------------------------------

In total, 52 studies concerning 118 biological tumor markers were included. Studies had been published between 1987 and 2017 (median 2007). A maximum of 13 markers was investigated by one study. The median number of patients per study included was 60 (range 21‐281). The median quality score was 6 out of 11 (range 3‐10). A low number of studies reported inclusion and exclusion criteria, and none of the studies gave a rational for the number of patients analysed (power analysis). This is due to the retrospective design of most studies. Patient characteristics and details of the assay used were generally described well (50 of 52 studies). Studies published from 2007 (median 7, range 4‐10) were of better quality than studies published before 2007 (median 6, range 3‐8) (*P* = .03).

3.2. Proliferation {#coa13540-sec-0019}
------------------

Ki‐67, a nuclear protein involved in cell proliferation, was described eleven times (Table [1](#coa13540-tbl-0001){ref-type="table"}). In five, high Ki‐67 proliferation index was related to better local control after radiotherapy (two out of five showed a trend, studies with low number of patients), either in univariate or multivariate analysis.[^7^](#coa13540-bib-0007){ref-type="ref"}, [^8^](#coa13540-bib-0008){ref-type="ref"}, [^9^](#coa13540-bib-0009){ref-type="ref"}, [^10^](#coa13540-bib-0010){ref-type="ref"}, [^11^](#coa13540-bib-0011){ref-type="ref"} In four, no relation with local control was found.[^12^](#coa13540-bib-0012){ref-type="ref"}, [^13^](#coa13540-bib-0013){ref-type="ref"}, [^14^](#coa13540-bib-0014){ref-type="ref"}, [^15^](#coa13540-bib-0015){ref-type="ref"} Also, in two other papers an inverse correlation was found, high Ki‐67 expression being a predictor for poor local control.[^16^](#coa13540-bib-0016){ref-type="ref"}, [^17^](#coa13540-bib-0017){ref-type="ref"} Interestingly, in the paper of Sakata et al the association with local recurrence was only found in patients treated by accelerated radiotherapy, not in the group treated by conventional radiotherapy.[^17^](#coa13540-bib-0017){ref-type="ref"} Another marker for proliferation is Proliferating Cell Nuclear Antigen (PCNA). Munck‐Wikland et al showed that non‐recurrent tumors had higher levels of PCNA expression (Table [1](#coa13540-tbl-0001){ref-type="table"}),[^18^](#coa13540-bib-0018){ref-type="ref"} again indicating that high proliferation contributes to good outcome after radiotherapy.

###### 

Proliferation markers in relation to outcome after primary radiotherapy in laryngeal cancer patients

<table><thead><tr class="header"><th><p>Author</p><p>Year</p></th><th>Marker</th><th>Method</th><th>Cut‐off</th><th>N</th><th>Stage</th><th>Side</th><th>Treatment</th><th>Outcome, definition</th><th><p>Univariate</p><p>HR/OR (95% CI)</p></th><th><p>Multivariate</p><p>HR/OR (95% CI)</p></th></tr></thead><tbody><tr class="odd"><td>Kwon 2015<a href="#coa13540-bib-0012" data-ref-type="ref"><sup>12</sup></a></td><td>Ki‐67</td><td>IHC</td><td>&gt;50%</td><td>42</td><td>T1‐2</td><td>Larynx</td><td>RT</td><td>Residual tumor &lt; 0.5 yrs</td><td>= 2.16 (0.40‐11.80)</td><td> </td></tr><tr class="even"><td>Rademakers 2015<a href="#coa13540-bib-0013" data-ref-type="ref"><sup>13</sup></a></td><td>Ki‐67</td><td>IHC</td><td>&gt;10% nuclear</td><td>128</td><td>T2‐4N0‐+</td><td>Larynx</td><td>ART</td><td>Time to local recurrence</td><td>=</td><td> </td></tr><tr class="odd"><td>Nichols 2012<a href="#coa13540-bib-0016" data-ref-type="ref"><sup>16</sup></a></td><td>Ki‐67</td><td>IHC</td><td>&gt;10% nuclear</td><td>75</td><td>T1‐2</td><td>Glottic</td><td>RT</td><td>Time to local recurrence</td><td>↓ 3.37 (1.14‐9.86)</td><td>↓ 4.86 (1.58‐15.00)</td></tr><tr class="even"><td>Wildeman 2009<a href="#coa13540-bib-0014" data-ref-type="ref"><sup>14</sup></a></td><td>Ki‐67</td><td>IHC‐TMA</td><td>OR per 10% increase, nuclear</td><td>59</td><td>T1‐3N0‐3</td><td>Larynx</td><td>RT</td><td>Local recurrence &lt; 2 yrs</td><td>= 0.71 (0.44‐1.15)</td><td> </td></tr><tr class="odd"><td>Rafferty 2008<a href="#coa13540-bib-0007" data-ref-type="ref"><sup>7</sup></a></td><td>Ki‐67</td><td>IHC</td><td>&gt;50% Continuous, nuclear</td><td>50</td><td>T2N0</td><td>Larynx</td><td>RT</td><td>Local recurrence</td><td><p>↑</p><p>=</p></td><td>=</td></tr><tr class="even"><td>Ahmed 2008<a href="#coa13540-bib-0008" data-ref-type="ref"><sup>8</sup></a></td><td>Ki‐67</td><td>IHC</td><td><p>&gt;10% nuclear</p><p>Continuous, nuclear</p></td><td>24</td><td>T1‐2</td><td>Glottic</td><td>RT</td><td>Persistence or local recurrence</td><td><p>↑ 0 (0‐∞)* (trend)</p><p>↑</p></td><td> </td></tr><tr class="odd"><td>Cho 2004<a href="#coa13540-bib-0010" data-ref-type="ref"><sup>10</sup></a></td><td>Ki‐67</td><td>IHC‐TMA</td><td>&gt;10% nuclear</td><td>123</td><td>T1‐2N0</td><td>Larynx</td><td>RT</td><td>Time to local recurrence</td><td>= 0.47 (0.18 −1.23)*</td><td>↑ 0.17 (0.06‐0.49)*</td></tr><tr class="even"><td>Condon 2002<a href="#coa13540-bib-0015" data-ref-type="ref"><sup>15</sup></a></td><td>Ki‐67</td><td>IHC</td><td>&gt;20% nuclear</td><td>21</td><td>T1‐2N0</td><td>Glottic</td><td>RT</td><td>Local recurrence &lt; 1 yrs</td><td>= 1.94 (0.32‐11.8)*</td><td> </td></tr><tr class="odd"><td>Motamed 2001<a href="#coa13540-bib-0009" data-ref-type="ref"><sup>9</sup></a></td><td>Ki‐67</td><td>IHC</td><td>Continuous, nuclear</td><td>28</td><td>T1aN0</td><td>Glottic</td><td>n.s.</td><td>Radioresistance, n.s.</td><td>↑ (trend)</td><td> </td></tr><tr class="even"><td>Sakata 2000<a href="#coa13540-bib-0017" data-ref-type="ref"><sup>17</sup></a></td><td>Ki‐67</td><td>IHC*</td><td>≥50%</td><td><p>130</p><p>51</p><p>79</p></td><td>T1‐2N0</td><td>Glottic</td><td><p>RT/ART</p><p>RT</p><p>ART</p></td><td>Local recurrence</td><td><p>↓ 2.66 (1.17‐6.08)*</p><p>= 1.32 (0.40‐4.38)*</p><p>↓ 5.11 (1.53‐17.04)*</p></td><td> </td></tr><tr class="odd"><td>Kropveld 1998<a href="#coa13540-bib-0011" data-ref-type="ref"><sup>11</sup></a></td><td>Ki‐67</td><td>IHC</td><td>Continuous</td><td>36</td><td>T2N0‐2</td><td>Larynx</td><td>RT</td><td>Locoregional recurrence</td><td>↑</td><td> </td></tr><tr class="even"><td>Munck 1993<a href="#coa13540-bib-0018" data-ref-type="ref"><sup>18</sup></a></td><td>PCNA</td><td>IHC</td><td>Continuous, nuclear</td><td>28</td><td>T1N0</td><td>Glottic</td><td>RT</td><td>Recurrent or persistent, n.s.</td><td>↑</td><td> </td></tr></tbody></table>

\*, (Subgroup) analysis performed by authors of this systematic review; "=", No relation with outcome; ↑, Positivity of marker associated with good outcome; ↓, Positivity of marker associated with poor outcome; ART, accelerated radiotherapy; CI, confidence interval; HR, hazard ratio; IHC, immunohistochemistry; n.s., not specified; OR, odds ratio; RT, conventional radiotherapy; TMA, tissue microarray; yrs, years.
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3.3. Angiogenesis and hypoxia {#coa13540-sec-0020}
-----------------------------

Eight studies investigating five angiogenesis or hypoxia associated markers were included (Table [S2](#coa13540-sup-0001){ref-type="supplementary-material"}). Hypoxia‐inducible factor 1α (HIF‐1α) was found to be a predictor of poor outcome after radiotherapy in two out of five studies.[^12^](#coa13540-bib-0012){ref-type="ref"}, [^14^](#coa13540-bib-0014){ref-type="ref"}, [^19^](#coa13540-bib-0019){ref-type="ref"}, [^20^](#coa13540-bib-0020){ref-type="ref"}, [^21^](#coa13540-bib-0021){ref-type="ref"} Hypoxia also induces CA‐IX expression in tumor cells. Two out of six studies investigating CA‐IX showed that positive expression predicted poor local control after radiotherapy.[^12^](#coa13540-bib-0012){ref-type="ref"}, [^14^](#coa13540-bib-0014){ref-type="ref"}, [^19^](#coa13540-bib-0019){ref-type="ref"}, [^20^](#coa13540-bib-0020){ref-type="ref"}, [^21^](#coa13540-bib-0021){ref-type="ref"}, [^22^](#coa13540-bib-0022){ref-type="ref"} Glucose transporter 1 (Glut‐1), osteopontin (OPN) and vascular endothelial growth factor (VEGF) were not associated with outcome after radiotherapy.[^12^](#coa13540-bib-0012){ref-type="ref"}, [^19^](#coa13540-bib-0019){ref-type="ref"}, [^21^](#coa13540-bib-0021){ref-type="ref"}, [^23^](#coa13540-bib-0023){ref-type="ref"}, [^24^](#coa13540-bib-0024){ref-type="ref"} Finally, a 26‐gene hypoxia signature was not associated with local control.[^25^](#coa13540-bib-0025){ref-type="ref"}

3.4. Apoptosis {#coa13540-sec-0021}
--------------

Apoptotic marker BCL‐2 was studied most extensively and expression was associated with local recurrence in two out of seven studies.[^14^](#coa13540-bib-0014){ref-type="ref"}, [^15^](#coa13540-bib-0015){ref-type="ref"}, [^16^](#coa13540-bib-0016){ref-type="ref"}, [^20^](#coa13540-bib-0020){ref-type="ref"}, [^26^](#coa13540-bib-0026){ref-type="ref"}, [^27^](#coa13540-bib-0027){ref-type="ref"}, [^28^](#coa13540-bib-0028){ref-type="ref"} Bxl‐xL showed a relation with poor local control in one study,[^14^](#coa13540-bib-0014){ref-type="ref"}, [^27^](#coa13540-bib-0027){ref-type="ref"} while Bax was associated with favourable outcome in one out of three studies.[^15^](#coa13540-bib-0015){ref-type="ref"}, [^27^](#coa13540-bib-0027){ref-type="ref"}, [^28^](#coa13540-bib-0028){ref-type="ref"} Bak, Survivin and BAG‐1 were studied once, and only BAG‐1 showed a trend towards poor local control.[^27^](#coa13540-bib-0027){ref-type="ref"}, [^29^](#coa13540-bib-0029){ref-type="ref"} (Table [S3](#coa13540-sup-0001){ref-type="supplementary-material"}).

3.5. P53 {#coa13540-sec-0022}
--------

The human tumor suppressor gene p53 was investigated extensively; fourteen studies found no relation with local control.[^8^](#coa13540-bib-0008){ref-type="ref"}, [^9^](#coa13540-bib-0009){ref-type="ref"}, [^10^](#coa13540-bib-0010){ref-type="ref"}, [^11^](#coa13540-bib-0011){ref-type="ref"}, [^14^](#coa13540-bib-0014){ref-type="ref"}, [^15^](#coa13540-bib-0015){ref-type="ref"}, [^23^](#coa13540-bib-0023){ref-type="ref"}, [^28^](#coa13540-bib-0028){ref-type="ref"}, [^30^](#coa13540-bib-0030){ref-type="ref"}, [^31^](#coa13540-bib-0031){ref-type="ref"}, [^32^](#coa13540-bib-0032){ref-type="ref"}, [^33^](#coa13540-bib-0033){ref-type="ref"}, [^34^](#coa13540-bib-0034){ref-type="ref"}, [^35^](#coa13540-bib-0035){ref-type="ref"} Only Narayana et al found poor local control in glottic carcinomas[^36^](#coa13540-bib-0036){ref-type="ref"} (Table [S4](#coa13540-sup-0001){ref-type="supplementary-material"}). Overall suggesting p53 not as a relevant marker for local control after radiotherapy.

3.6. Cell cycle {#coa13540-sec-0023}
---------------

FADD was not associated with local control, whereas phosphorylated FADD only showed a relation with better local control in glottic tumors, but not in supraglottic tumors.[^37^](#coa13540-bib-0037){ref-type="ref"}, [^38^](#coa13540-bib-0038){ref-type="ref"} Cyclin D1 showed some contradictory results; three out of five studies did not show a relation, while Yoo et al found cyclin D1 to be a predictor for better local control and Chang et al for poor local control after radiotherapy.[^7^](#coa13540-bib-0007){ref-type="ref"}, [^14^](#coa13540-bib-0014){ref-type="ref"}, [^37^](#coa13540-bib-0037){ref-type="ref"}, [^39^](#coa13540-bib-0039){ref-type="ref"}, [^40^](#coa13540-bib-0040){ref-type="ref"} P16, P21 (both three studies) and p27 showed no relation with local control, as well as retinoblastoma gene (Rb)[^14^](#coa13540-bib-0014){ref-type="ref"}, [^15^](#coa13540-bib-0015){ref-type="ref"}, [^30^](#coa13540-bib-0030){ref-type="ref"}, [^32^](#coa13540-bib-0032){ref-type="ref"}, [^41^](#coa13540-bib-0041){ref-type="ref"} (Table [S5](#coa13540-sup-0001){ref-type="supplementary-material"}).

3.7. COX‐2 {#coa13540-sec-0024}
----------

Cyclooxygenase‐2 (COX‐2) was described four times (Table [S6](#coa13540-sup-0001){ref-type="supplementary-material"}), two studies showed a relation between positive expression and poor local control, in either univariate of multivariate analysis,[^10^](#coa13540-bib-0010){ref-type="ref"}, [^42^](#coa13540-bib-0042){ref-type="ref"} whereas two others did not.[^12^](#coa13540-bib-0012){ref-type="ref"}, [^14^](#coa13540-bib-0014){ref-type="ref"}

3.8. EGFR {#coa13540-sec-0025}
---------

The epidermal growth factor receptor (EGFR) is a well‐known and extensively studied biological tumor marker. Protein expression of EGFR in relation to local control after radiotherapy in laryngeal cancer patients has been studied in ten independent studies (Table [S7](#coa13540-sup-0001){ref-type="supplementary-material"}).[^7^](#coa13540-bib-0007){ref-type="ref"}, [^8^](#coa13540-bib-0008){ref-type="ref"}, [^14^](#coa13540-bib-0014){ref-type="ref"}, [^16^](#coa13540-bib-0016){ref-type="ref"}, [^23^](#coa13540-bib-0023){ref-type="ref"}, [^26^](#coa13540-bib-0026){ref-type="ref"}, [^39^](#coa13540-bib-0039){ref-type="ref"}, [^43^](#coa13540-bib-0043){ref-type="ref"}, [^44^](#coa13540-bib-0044){ref-type="ref"}, [^45^](#coa13540-bib-0045){ref-type="ref"} Only Miyaguchi et al found a relation between positivity of EGFR and recurrence,[^45^](#coa13540-bib-0045){ref-type="ref"} thereby concluding EGFR is not a relevant marker.

3.9. DNA content {#coa13540-sec-0026}
----------------

Seven, mostly older studies (6 of 7 ≤1995) investigated DNA ploidy and compared diploid with aneuploid tumors. Three found no relation with local control, while Toffoli et al found that diploid tumors showed poor local control and three others found a relation with better local control after radiotherapy (Table [S8](#coa13540-sup-0001){ref-type="supplementary-material"}).[^18^](#coa13540-bib-0018){ref-type="ref"}, [^46^](#coa13540-bib-0046){ref-type="ref"}, [^47^](#coa13540-bib-0047){ref-type="ref"}, [^48^](#coa13540-bib-0048){ref-type="ref"}, [^49^](#coa13540-bib-0049){ref-type="ref"}, [^50^](#coa13540-bib-0050){ref-type="ref"}, [^51^](#coa13540-bib-0051){ref-type="ref"}

3.10. Genome‐wide expression profiling {#coa13540-sec-0027}
--------------------------------------

Instead of analysing individual, mostly well‐known and frequently investigated biological tumor markers, it is also possible to perform genome wide expression profiling for example by using mRNA expression microarrays. One study using gene expression data to discover markers for radiotherapy outcome in laryngeal cancer was identified. De Jong et al studied 52 laryngeal cancer patients with or without a local recurrence after radiotherapy.[^52^](#coa13540-bib-0052){ref-type="ref"} Expression of the stem cell‐associated marker CD44 showed a relation with local recurrence (HR 20.2, 95%CI 3.4‐172.3), and this was confirmed by immunohistochemistry for CD44 in an independent set of 76 laryngeal cancer patients (HR 15.2, *P* \< .01). However, gene sets defining hypoxia, radiosensitivity or proliferation did not correlate with local recurrence.

3.11. Micro‐RNAs {#coa13540-sec-0028}
----------------

Micro‐RNAs were investigated by two (Table [S9](#coa13540-sup-0001){ref-type="supplementary-material"}). Maia et al found miR‐296‐5p associated with poor locoregional control and de Jong et al found miR‐203 as predictor of good local control after radiotherapy.[^53^](#coa13540-bib-0053){ref-type="ref"}, [^54^](#coa13540-bib-0054){ref-type="ref"}

3.12. Miscellaneous biological tumor markers {#coa13540-sec-0029}
--------------------------------------------

An overview of the predictive value of other markers is given in Table [S10](#coa13540-sup-0001){ref-type="supplementary-material"}. All of these markers were studied once. ATM, LOH at 9p21, LOH at 3p21, BCCIP, Cortactin, ERCC1 and EPOR were not predictive of outcome,,[^12^](#coa13540-bib-0012){ref-type="ref"}, [^15^](#coa13540-bib-0015){ref-type="ref"}, [^21^](#coa13540-bib-0021){ref-type="ref"}, [^28^](#coa13540-bib-0028){ref-type="ref"}, [^31^](#coa13540-bib-0031){ref-type="ref"}, [^55^](#coa13540-bib-0055){ref-type="ref"} whereas EpCAM/BerEP4, IGF‐1R, HDAC1, NF‐κB, β1 integrin and TGF‐α were associated with poor local control after radiotherapy.[^26^](#coa13540-bib-0026){ref-type="ref"}, [^30^](#coa13540-bib-0030){ref-type="ref"}, [^44^](#coa13540-bib-0044){ref-type="ref"}, [^56^](#coa13540-bib-0056){ref-type="ref"}, [^57^](#coa13540-bib-0057){ref-type="ref"}, [^58^](#coa13540-bib-0058){ref-type="ref"}

4. DISCUSSION {#coa13540-sec-0030}
=============

4.1. Summary of main results {#coa13540-sec-0031}
----------------------------

In this systematic review, a comprehensive overview of studies reporting on biological tumor markers in relation to local control after primary radiotherapy in laryngeal cancer patients is presented. None of the investigated markers or clusters of markers showed consistent evidence for a positive or negative relation with local control. There is some evidence for Ki‐67/proliferation towards better local control (Table [1](#coa13540-tbl-0001){ref-type="table"}). Interestingly, two well‐known markers in HNSCC, EGFR and P53, showed consistent evidence for not being predictive of local control after primary radiotherapy.

4.2. Overall completeness, quality and applicability of evidence {#coa13540-sec-0032}
----------------------------------------------------------------

An extensive search has been performed to identify all published markers for local control after radiotherapy in laryngeal cancer. As found in this systematic review study quality varies among studies, almost all studies are retrospective cohorts, some do not report details on radiotherapy schedule, or outcome chosen, while others inadequately describe the interpretation of the assay used for detection of the biological tumor marker. In 2005, the REMARK criteria were published to encourage transparent and complete reporting in prognostic marker studies.[^4^](#coa13540-bib-0004){ref-type="ref"} However, also after introduction of REMARK, prognostic biological marker studies are still poorly reported.[^59^](#coa13540-bib-0059){ref-type="ref"} Remarkably, studies included in this systematic review did have a slightly better quality after 2006 than before. Adequate reporting is essential for drawing conclusions from a systematic review and should be emphasised for new publications.

Despite the fact that this systematic review included studies on relatively homogeneous patient populations (eg only laryngeal cancer; only patients treated with primary radiotherapy), it was still difficult to compare studies analysing the same biological tumor marker, because of multiple factors. First, most studies used small, heterogeneous patient populations. Some studies include both glottic and supraglottic tumors, others evaluate those separately, with sometimes different outcomes. For example, pFADD positivity was associated with better local control in glottic, but not in supraglottic laryngeal cancer patients.[^37^](#coa13540-bib-0037){ref-type="ref"}, [^38^](#coa13540-bib-0038){ref-type="ref"} Glottic and supraglottic tumors often present with different symptoms, at different stages.[^60^](#coa13540-bib-0060){ref-type="ref"}, [^61^](#coa13540-bib-0061){ref-type="ref"}, [^62^](#coa13540-bib-0062){ref-type="ref"} Therefore, supra‐ and glottic tumors might be regarded as distinct entities. Although we only included primary radiotherapeutically treated patients, different treatment schedules (conventional vs. accelerated) could have influenced the results, as for Ki‐67 and EGFR. Furthermore, the number of patients is low (median number of patients is 60) and a rationale for the number of included patients is not given. There are differences in methodology, such as different antibodies used, different cut‐offs used for a marker, often without giving a rationale for the cut‐off used. Finally, different definitions of outcome after radiotherapy are used such a local recurrence within 6 months while others use local recurrence within 5 years, where can be discussed if a local recurrence after 5 years should be considered as a recurrence or as a second primary tumor.

4.3. Potential biases in review {#coa13540-sec-0033}
-------------------------------

The most important potential bias in this review is publication bias, especially research with negative results might have not been published.

4.4. Comparison with other reviews {#coa13540-sec-0034}
----------------------------------

Also for other tumor sides, there is no consistent evidence for the predictive value of Ki‐67 for radiation response, though Ki‐67 positivity is likely to be a poor prognostic factor for breast and cervical cancer, irrespectively of treatment modality.[^63^](#coa13540-bib-0063){ref-type="ref"}, [^64^](#coa13540-bib-0064){ref-type="ref"}

A review by Bossi et al, shows the same results for EGFR in other HNSCC tumor sites.[^65^](#coa13540-bib-0065){ref-type="ref"} However, a relation with EGFR positivity and poor outcome after primary radiotherapy was found in some large groups of HNSCC patient treated with an accelerated radiotherapy schedule.[^65^](#coa13540-bib-0065){ref-type="ref"}

Previous p53 research showed p53 mutations as predictor of poor local control after primary radiotherapy in a variety of tumor sites, including HNSCC.[^66^](#coa13540-bib-0066){ref-type="ref"} A potential reason that we did not find a relation might be that in the studies included in our analysis, p53 was mostly studied by immunohistochemistry, not by mutational analysis. Research has shown that immunohistochemical staining is not always strongly correlated with mutational status, but optimisation, standardisation and validation of p53 immunohistochemistry could reliably predict p53 mutations.[^67^](#coa13540-bib-0067){ref-type="ref"}

5. IMPLICATIONS FOR CLINICAL PRACTICE AND RESEARCH {#coa13540-sec-0035}
==================================================

Biological tumor markers that are strongly predictive of response to primary radiotherapy could be helpful in selecting patients who are in need for additional (or intensified) treatment or alternative treatment modalities such as surgery. Biological tumor markers could also contribute to identify new potential targets for therapeutic intervention. We found some evidence for Ki‐67/proliferation being predictive of better local control after primary radiotherapy, whereas EGFR and P53 showed consistent evidence for not being predictive of local control after primary radiotherapy. Cell proliferation is one of the most essential biological processes in oncogenesis.[^68^](#coa13540-bib-0068){ref-type="ref"} Ki‐67 is present in all the active phases of the cell cycle (G1, G2, M and mitosis), but absent in resting cells (G0),[^69^](#coa13540-bib-0069){ref-type="ref"} suggesting a role for Ki‐67 as a potential predictor of outcome after radiotherapy, as radiotherapy affects dividing cells. However, the predictive value of Ki‐67 for response to primary radiotherapy in laryngeal cancer is currently unclear and Ki‐67 assessment methods lack standardisation, thereby preventing clinical implementation. More research in well‐defined study populations is needed to elucidate the potential predictive role of Ki‐67 in outcome after primary radiotherapy and thereby potential application.
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